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Proper fluid management is crucial for the management of critically ill patients. However, there is a continuing
debate about the choice of the fluid, i.e., crystalloid vs. colloid. Colloid solution is theoretically advantageous to the
crystalloid because of larger volume effect and less interstitial fluid accumulation, and hydroxyethyl starch (HES) is
most frequently used for perioperative setting. Nevertheless, application of HES solution is relatively limited due to
its side effects including renal toxicity and coagulopathy. Since prolonged presence of large HES molecule is
responsible for these side effects, rapidly degradable HES solution with low degree of substitution (tetrastarch)
supposedly has less potential for negative effects. Thus, tetrastarch may be more frequently used in the ICU setting.
However, several large-scale randomized trials reported that administration of tetrastarch solution to the patients
with severe sepsis has negative effects on mortality and renal function. These results triggered further debate and
regulatory responses around the world. This narrative review intended to describe the currently available evidence
about the advantages and disadvantages of tetrastarch in the ICU setting.
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In the perioperative setting, goal-directed fluid manage-
ment using hydroxyethyl starch (HES) preparation has
been successfully implemented [1,2]. However, recent
randomized controlled studies targeted for critically ill
patients demonstrated contradictory results. In this nar-
rative review, advantages and disadvantages of HES
preparation, especially most recently developed HES so-
lution with degree of substitution of 0.4 (tetrastarch,
HES 130/0.4 or HES 130/0.42), which has low-molecular
weight and is rapidly degradable, for fluid resuscitation
in ICU or ER setting is discussed.
Review
The proposed advantages and disadvantages of colloid
against crystalloid are summarized in the Table 1 [3].
Characteristics of HES
Starch is a branched polymer of glucose, and it has poor
solubility and is rapidly metabolized by α-amylase. To
make the starch molecule more soluble and provide* Correspondence: ykotake@med.toho-u.ac.jp
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unless otherwise stated.clinically relevant persistence in the circulation, some of
hydroxyl moiety of starch molecule is substituted with
hydroxyethyl residue. The degree of substitution (DS)
represents the ratio between hydroxymethylated and
unsubstituted portion. C2/C6 ratio represents the pos-
ition of the carbon atom skeleton of glucose where the
substitution predominantly occurs. HES molecule with
lower DS and C2/C6 ratio is more susceptible to the ef-
fects of amylase and more rapidly eliminated from the
circulation than HES molecule with higher DS and C2/
C6 ratio [4-6]. The number and the size of the metabo-
lized HES molecule remained in the circulation (in vivo
molecular weight) play important roles on the volume
effects and side effects of the HES solution [7,8]. Thus,
the development has been aimed for HES preparations
with low DS, and currently, HES preparation with DS of
0.4 or 0.42 (HES 130/0.4 and HES 130/0.42) is the most
advanced solution to date. These solutions are some-
times called tetrastarch according to the number of their
DS. Characteristics of several HES preparations as well
as other colloids such as albumin and gelatin are sum-
marized in Table 2 [9-15]. In this article, the advantages
and disadvantages of tetrastarch against other colloids
and crystalloids are reviewed.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Claimed advantages and disadvantages of colloid solution versus crystalloid solution
Solution Advantages Disadvantages
Colloids Smaller infused volume Renal dysfunction (dextran > HES > albumin)
Prolonged increase in plasma volume Coagulopathy (older HES > tetrastarch > albumin)
Less peripheral edema Pulmonary edema (capillary leak syndrome)
Endothelial protection Pruritis (HES, dextran > albumin)
Anaphylaxis (dextran > HES > albumin)
Greater cost (albumin > other synthetic colloids)
Crystalloid Lower cost Short-term increase in intravascular volume
Greater urinary flow Short-term hemodynamic improvement
Interstitial fluid replacement Interstitial fluid accumulation
Modified from reference [3].
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Smaller infused volume and prolonged increase in
plasma volume
Theoretically, colloid solution exerts three to four times
larger volume expansion compared to crystalloid solu-
tion. This paradigm has been confirmed in healthy vol-
unteers [16], but the volume effect seems much smaller
than such theoretical value in the clinical situations. Ac-
tually, most of the studies reported that both HES and
albumin demonstrated 1.4 to 1.8 times larger volume











Albumin 4 20–29 80 n/a
20 100–120 200 ~ 400
Dextran 70 6 56–68 120 28 ~ 42
Dextran 40 10 168–191 200 6
Fluid gelatin 4 42 70 2 ~ 7
90 7
Urea-linked gelatin 3.5 25–29 70 ~ 80 2 ~ 7
HES 670/0.75 6 25–30 100
HES 200/0.5 6 30–37 100 3 ~ 4
HES 70/0.5 6 80 ~ 90
HES 200/0.5 10 59–82 145 3 ~ 4
HES 130/0.4 6 36 100 <1
HES 130/0.42 6
Modified from references [9-11]. HES products are summarized as in vitro molecular w
volume (%). The number of plus sign suggests the semi-qualitative comparison betweauthors concluded that the difference was not clinically
relevant, we assume that the difference remains clinically
relevant since favorable outcome could be achieved with
even moderately restrictive fluid regimen in patients
with acute respiratory distress syndrome [22,23].
Endothelial protection
Several studies demonstrated anti-inflammatory proper-
ties and endothelial protection by tetrastarch [24-28].
However, relevant clinical study is not available due to





Carrier solution Effect on
hemostasis
Comments






Na 154 mEq/l 0 ~ +
Cl 120 mEq/l
Na 145 mEq/l 0 ~ +
Cl 145 mEq/l
20 ml/kg Lactate Ringer ++(+)
33 ml/kg +
20 ml/kg Either saline or
balanced solution
0 ~ +
20 ml/kg + Used in VICEP
study [12]
50 ml/kg Either saline or
similar to acetate
Ringer but no Ca
0 ~ + Used in CHEST
study [13] and
CRYSTMAS study [14]
33 ml/kg Acetate Ringer Used in 6S trial [15]
eight/degree of substitution. aExpressed as plasma volume increase/administered
en each item.
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vascular permeability [30-33]. In vitro model of coronary
vasculature, HES 130/0.4 partially attenuated the negative
effects of glycocalyx destruction by heparinase [34,35].
This finding potentially suggests the possible protective
effects of tetrastarch molecule in inflammation-related
glycocalyx damage.Disadvantages of tetrastarch
Renal dysfunction
Overview Older HES preparations are known to nega-
tively affect the renal integrity. However, tetrastarch
undergoes rapid metabolism and is generally assumed
that such side effects are less clinically relevant. How-
ever, recent reports suggest even tetrastarch increases
the risk of acute kidney injury and renal replacement
therapy in ICU patients. In this section, we focused on
the interpretation of recent reports about this topic.Non-clinical studies
In vitro study
In vitro study using cultured renal tubular cells demon-
strated cytotoxic effect of HES 130/0.4 while crystalloid
and albumin demonstrated protective effect [36]. The
author estimated that exposure of HES 130/0.4 concen-
tration over 10 mg/ml for more than 4 h may exert dele-
terious effect on proximal renal tubular cells. Since no
metabolism presumably occurs in their experimental
setting, this result suggests that prolonged exposure of
unmetabolized HES molecule may negatively affect the
renal integrity.Animal, in vivo studies in severe sepsis model
Several animal studies also investigated renal effects of
HES 130/0.4 in septic shock model. In rats, HES 130/0.4
negatively affected renal function compared to sham-
operated animals [37]. However, interpretation of the
data is somewhat difficult since the effects of HES 130/
0.4 and crystalloid were not directly compared. In ewes,
initial resuscitation of HES and crystalloid resulted similar
serum creatinine concentration as well as microscopic
finding of renal tubules [38,39]. These data suggest that
resuscitation with HES may not negatively affect renal
function in septic shock animals.Clinical studies
Prospective study in penetrating trauma patients
(FIRST study)
In resuscitation of penetrating trauma victims [18], early
goal-directed therapy using HES 130/0.4 resulted in milder
renal damage than that using saline.Repetitive administration of large dose in traumatic brain
injury patients
In traumatic brain injury patients [40], cumulative dose
of 19 ± 16 l of HES 130/0.4 (max 66 liter) did not nega-
tively affect creatinine clearance and serum creatinine [40].
Retrospective study in ICU patients
A retrospective study demonstrated that use of HES
130/0.4 was not a risk factor of acute kidney injury in
patients who stayed more than 72 h in the ICU [41].
Retrospective study in severe sepsis patients
Bayer et al. reported the sequential change of incidence
of renal replacement therapy when the principle fluid
choice was shifted from HES to gelatin to crystalloid
[19,42] in patients with severe sepsis and postcardiac
surgical patients [21]. The authors claimed that the
study design was prospective and sequential; we think
that the results should be interpreted as a retrospective
analysis. They found that the incidence was highest in
the period when HES was predominantly used compared
to the period when gelatin or crystalloid was used. They
concluded that administration of HES compromised
renal function and increased the risk of renal replace-
ment therapy. In these studies, the cumulative dose as
well as the duration of HES administration was not re-
ported. Thus, there is a fair possibility that HES had
been used on multiple days during their ICU stay.
Prospective, randomized trial in severe sepsis patients
(6S trial)
In this randomized, control trial (RCT) [15], 90-day
mortality and the incidence of RRT were compared be-
tween buffer-based HES 130/0.42 and acetate Ringer so-
lution in severe sepsis patients in ICU. In this trial, HES
had been administered 3 days and more in about 50% of
the participants and median cumulative dose of HES
was reported as 44 ml/kg. Unfortunately, the largest
quartiles of cumulative dose are not reported, and the
relationship between cumulative dose and outcomes are
not analyzed.
Prospective, randomized trial in ICU patients (CHEST study)
In this RCT [13], 90-day mortality, incidence of acute
kidney injury (AKI) and requirement of renal replace-
ment therapy were compared between saline-based HES
130/0.4 and saline. The inclusion criteria were less strict
than the 6S trial and ICU patients who had the indica-
tion of fluid administration underwent randomization.
The percentage of patients with sepsis was about 30% in
both groups, and about 15% of the subjects received
HES before randomization in both groups. The number
of days with HES treatment as well as the cumulative
dose was not explicitly described. It is noteworthy that
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fluid balance was significantly positive especially in the
latter part of the study period. There was no difference
of 90-day mortality, but the number of patients who
underwent renal replacement therapy was marginally
but significantly higher in patients assigned to HES
group (p = 0.04). The subgroup analysis revealed that the
HES did not negatively affect the primary outcome in
patients with sepsis and AKI before randomization. On
the contrary, secondary cardiovascular failure was sig-
nificantly reduced in patients randomized to HES group.
Prospective, randomized trial in severe sepsis patients
(CRYSTMAS study)
In this RCT [14], hemodynamic effects, incidence of
renal injury assessed with risk, injury, failure, loss,
end-stage renal disease (RIFLE) criteria as well as several
biomarker concentrations were compared between
saline-based HES 130/0.4 and saline in severe sepsis
patients. Although this study was much smaller than
6S trial and CHEST study, the target of fluid resuscitation
and allowable limit of HES were clearly defined as
50 ml/kg on first day and 25 ml/kg afterward. There
was no difference of AKI incidence assessed by RIFLE
criteria and biomarkers.
Meta-analysis
This meta-analysis [43] investigated the effects of vari-
ous HES preparations of HES on renal function. This
report concluded that HES was associated with a signifi-
cant increased risk of mortality and acute kidney injury.
This conclusion is derived from the secondary analysis
from ten articles including 6S trial, CHEST study, and
CRYSTMAS study, but results from studies using differ-
ent HES preparation were also included [12,44].
Prospective, randomized trial in the treatment of
hypovolemic shock (CRISTAL trial)
This recent RCT [45] compared colloid and crystalloid on
the 28-day mortality, 90-day mortality, renal replacement-
free days, ventilator-free days, and vasopressor-free days
in patients with hypovolemic shock from various origins.
Although this study is not solely focused on HES prep-
aration, the results may be extrapolated to the effects of
HES 130/0.4 since it was used in 70% of the colloid
group. There was no difference in the 28-day mortality,
but most of the secondary outcomes were better with
the colloid group.
Clinical implications of HES-induced renal impairment
According to the in vitro study, the prolonged exposure
of native HES molecule may be injurious to the renal tis-
sue. Thus, the rapid degradation and elimination of HES
molecule may be pivotal to preserve renal integrity. It isyet to be known whether the activity of α-amylase, main
metabolic pathway of HES, is intact or impaired in pa-
tients with severe sepsis. From this standpoint, the renal
damage of HES may be dose-dependent in certain popu-
lations and repetitive administration near the upper limit
of the maximal dose to the patients with sepsis may not
be advisable. Additionally, recent reports highlight the
implications of chloride on renal function. This issue is
more important for saline-based HES preparation. In
volunteers, saline infusion reduced the renal microvascu-
lar blood flow compared to balanced solution [46]. Fur-
thermore, chloride-restrictive fluid management reduced
renal damage in ICU patients [47], and postoperative
hyperchloremia increased the mortality risk in surgical
patients [48]. Thus, excessive or liberal administration of
chloride may not be also advisable.
Coagulopathy
Overview
Currently, five major pathways have been identified:
(1) dilution of coagulation factors, (2) binding and in-
activation of factor VIII (fVIII) and von Willebrand's
factor (vWF), (3) inhibition of glycoprotein receptor
IIb/IIIa (GP IIb/IIIa) on the surface of activated plate-
let, (4) inhibition of binding between GP IIb/IIIa and
vWF or fibrinogen, and (5) acceleration of fibrin deg-
radation [10,49]. Accordingly, the effects of HES on
dilution or binding and inactivation of fVIII or vWF
may be evaluated with the plasma concentration of fVIII
and vWF [50-53]. Inhibition of GP IIb/IIIa can be quanti-
tated with platelet aggregometry [54], and overall effects
may be estimated with viscoelastic analysis of coagulation
such as rotational thromboelastometry [55].
Previous data indicate that these effects of HES on co-
agulation clearly depend on its pharmacokinetic profile,
and prolonged presence of large HES molecule sup-
posedly has the large impact on coagulation [56]. Thus,
tetrastarch should be least suppressive of coagulation
system (Table 2). Furthermore, the presence of calcium
in the carrier solution may attenuate the negative impact
of HES on coagulation [57]. Unfortunately, most of the
currently available data are derived from perioperative
setting, and only small numbers of studies from ICU
are available.
Clinical studies
Viscoelastic analysis with postcardiac surgery patients
This study compared the effects of 15 ml/kg of HES
130/0.4, HES 200/0.5, and 4% albumin on thromboelas-
tometric tracing in patients after cardiac surgery in the
ICU [58]. The author found that clot formation time
and maximal clot firmness was decreased immediately
after the infusion of both HES preparations. Such changes
were partially reversed 2 h after the infusion. On the
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thromboelastometry. However, they found no difference
of the amount of chest tube drainage between the three
study groups.
The same authors compared the effects of 28 ml/kg
of HES 130/0.4, gelatin, and crystalloid in the similar
setting described in the previous paragraph [59]. The
author found that clot formation time and maximal clot
firmness were decreased in the dose-dependent manner
after the infusion of HES 130/0.4 and colloid. Only the
changes after HES 130/0.4 infusion were returned to the
pre-infusion level. On the contrary, crystalloid slightly
but significantly potentiated coagulation. Again, they found
no difference of the amount of chest tube drainage between
the three study groups.
Meta-analysis of postcardiac surgical patients
This meta-analysis [60] selected 18 trials to examine the
effects of HES on coagulation system in patients under-
going cardiopulmonary bypass. The author found that
HES significantly increase the risk of postoperative blood
loss and reoperation compared to albumin. The selected
studies include the use of different types of HES prepar-
ation as well as various clinical contexts such as pump
prime, intraoperative fluid administration, and fluid
management in the ICU, and therefore, the effects of
postoperative use of tetrastarch in the ICU on coagula-
tion is inconclusive. However, the author commented
that the analysis did not provide reassurance of a safety
profile of tetrastarch due to the fact that sensitivity
analysis did not found statistical difference between pen-
tastarch and tetrastarch.
Repetitive administration of large dose in traumatic brain
injury patients
This study is already mentioned in the renal impairment
section. Most of the coagulation parameters such as
platelet count, fibrinogen concentration, prothrombin
time, partial thromboplastin time, and thromboelasto-
graphic analysis were comparable between HES 130/0.4
group and HES 200/0.5 supplemented with albumin
group. However, plasma concentrations of FVIII and
vWF were significantly higher in the HES 130/0.4 group.
Such data can be extrapolated as repetitive administra-
tion of HES 130/0.4 may not have deleterious effect on
coagulation in patients without major predisposing fac-
tor of coagulation dysfunction such as postcardiac surgi-
cal patients or sepsis [40].
Post hoc analysis of prospective, randomized trial in
severe sepsis patients (6S trial)
In this analysis [61], the authors found increased inci-
dence of bleeding in patients who were assigned to HES
130/0.42 group. Multivariate analysis revealed significantlyincreased risk of any bleeding in patients treated with
buffer-based HES 130/0.42 compared to that with acetate
Ringer's solution.
Clinical implications of HES-induced coagulopathy
Most of the previous studies indicate that the persistent
presence of large HES molecule in the circulation may
be responsible to the HES-induced coagulopathy. Thus,
tetrastarch supposedly has more favorable profile on co-
agulation in patients without underlying coagulation dis-
orders. However, risk–benefit ratio should be carefully
evaluated in special populations such as patients after
cardiopulmonary bypass and patients with sepsis.
The following interventions may successfully attenuate
the effects of tetrastarch on coagulation. First, consider
fibrinogen. Although obtained from perioperative set-
ting, abnormalities of maximal clot firmness from rota-
tional thromboelastometry after major bleeding and HES
130/0.4 administration can be successfully reversed by
the administration of fibrinogen concentrates [62,63].
These data intuitively suggest that monitoring and prompt
supplementation of fibrinogen is imperative to prevent the
consequences of HES-induced coagulation dysfunction.
Second, consider supplement of calcium. Adequate ion-
ized calcium is essential for coagulation system. However,
saline-based HES 130/0.4, which is currently available in
Japan, does not contain calcium in its carrier solution
and predisposes the patients to potential hypocalcemia.
Although a study with healthy volunteers demonstrated
attenuated ADP-induced platelet aggregation and no
difference of viscoelastic analysis in saline-based HES
130/0.4 compared to balanced HES 130/0.42 [64], we
believe that careful monitoring and timely supplemen-
tation of calcium is also essential to attenuate HES-
induced coagulopathy.
Pulmonary edema (capillary leak syndrome)
This is a relatively common concern about colloid ad-
ministration that extravasated colloid may accentuate
interstitial fluid accumulation and worsen pulmonary
edema. However, the recent study using extravascular
lung water evaluation by transpulmonary thermodilution
method failed to substantiate this concern [65].
Pruritis and anaphylaxis
These issues may also be related to the molecular size of
HES, and the incidences of such side effects are rela-
tively low in tetrastarch [5,66-69]. However, pruritus and
skin rashes more frequently occurred in the CHEST
study that compared HES 130/0.4 with saline [13].
Economical and regulatory issues
This issue is dependent on the price of HES, albumin,
and crystalloid solution. In Japan, saline-based HES 130/
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tion, but albumin is approximately ten times more ex-
pensive than saline-based HES 130/0.4. Thus, the use of
tetrastarch may be economically justifiable in Japan.
However, the concern about renal damage caused by
HES triggered various responses from each country. For
example, European regulatory agency recommends with-
drawal of HES preparation and several countries have
already implemented such policy. In the US, the authority
provided additional warning that made HES contraindi-
cated to septic patients. In Japan, the authority made add-
itional comment into the package insert of HES 130/0.4
basically stating ‘HES 130/0.4 may worsen patients' condi-
tion when administered to resuscitate relative hypovol-
emic state in critically ill patients including severe sepsis.
HES 130/0.4 is indicated if therapeutic benefits clearly
outweigh such risk’.
Conclusions
Currently, the advantages of the tetrastarch can be sum-
marized as the following two issues. First, more efficient
restoration of circulating blood volume with less intersti-
tial fluid accumulation compared to crystalloid. Second,
almost equivalent volume effect can be expected with
much less cost compared to albumin. On the contrary,
the disadvantage of tetrastarch is possible renal damage
when given to critically ill patients for several days.
Therefore, maximal advantages can be expected when
given to the patients who is hypovolemic not caused by
severe sepsis. Furthermore, we believe that it is impera-
tive to define the cumulative dose limit of tetrastarch
over several days.
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